“The next new $1trn stock will be…”

There are a very select few stocks that have seen their market cap exceed $1trn. And those that bought shares before that milestone will be very happy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The flag of the United States of America flying in front of the Capitol building

Image source: Getty Images

Since The Motley Fool’s mission statement is to make the world smarter, happier and richer, we asked some of our freelance writers which US stocks they think might be next to crack the $1trn threshold — potentially making shareholders very happy indeed!

Berkshire Hathaway

What it does: Warren Buffett’s diversified holding company uses an insurance float model to invest in dozens of businesses.

By Charlie CarmanBerkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) has broken the $700bn market capitalisation barrier, but it’s never reached the trillion-dollar threshold. I think that’s only a matter of time. As I write, the company would need to deliver a 36% share price gain to achieve this landmark.

From 1965 to 2022, Berkshire Class A stock achieved a 19.8% compound annual growth rate. Returns have slowed since the turn of the millennium, but the annual average remains firmly in double digits.

Recent results have been encouraging. In the first quarter, Berkshire posted a $35.5bn profit and accelerated its share repurchases, buying back $4.4bn of its own stock.

A major risk facing the company is the potential loss of investor confidence that could result from its CEO’s looming departure. After all, Buffett is 92.

However, his successor Greg Abel has already taken on many responsibilities, suggesting the handover could be less problematic than some fear.

Charlie Carman owns shares in Berkshire Hathaway. 

Berkshire Hathaway

What it does: Berkshire Hathaway is a diversified conglomerate that operates in sectors including insurance and retail and owns a stock portfolio.

By Christopher Ruane. The famed investor Warren Buffett has built Berkshire Hathaway over the course of decades.

Since taking the company over in 1965, Buffett has achieved a compounded annual gain of 19.8% in its per-share market value.

Some years are markedly better than others. In general, I think the defensive nature of many Berkshire businesses means that it can do well when the wider market stumbles. In 2007, for example, its compounded annual gain was 28.7% while the benchmark S&P 500 only achieved 5.5%.

The economy looks weak again to me, but one big difference is Berkshire’s massive position in Apple. If tech stocks including Apple fall, that could hurt Berkshire’s share price.

But I think the company’s broadly defensive asset base and Buffett’s steady hand on the tiller could help Berkshire ride out the next storm well. Its shares have risen 81% in five years and today the market capitalisation is $736bn.  

Christopher Ruane does not own shares in any of the companies mentioned.

Eli Lilly

What it does: Eli Lilly is a global healthcare company with products spanning oncology, immunology, diabetes and neurology.

By Ben McPoland. I think biopharma giant Eli Lilly (NYSE: LLY) could become the newest $1trn stock. Its market cap of $435bn already makes it one of the largest companies in the world.

The firm has a packed late-stage pipeline of potential blockbusters. One is its Alzheimer’s treatment, donanemab,which has successfully slowed memory and thinking decline in a rigorous phase 3 trial.

A second is Mounjaro, which is a medicine already used by people with type 2 diabetes. It is currently being assessed by US regulators and the NHS as a repositioned treatment for weight loss.

Needless to say, a proven and safe treatment for obesity (which is a global health issue) could be a huge deal for the company. Indeed, some analysts think it could become the biggest selling drug ever. And it could be approved by the end of this year. 

One risk is that this huge potential is already priced into the stock, with its trailing P/E of 72. Any disappointing regulatory news could hit the share price hard.  

Ben McPoland does not own shares in Eli Lilly.

The Motley Fool UK has recommended Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how many British American Tobacco shares it takes to earn a £1,000 monthly second income

Is an AI-resistant business with a 5.38% dividend yield a good choice for investors looking for a second income in…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

1,001 Barclays shares bought 12 months ago are now worth…

Barclays shares have delivered excellent returns over the last year. But can the FTSE 100 bank keep outperforming? Royston Wild…

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

Get started on the stock market: 3 ‘safe’ shares for beginner UK investors to consider

Kicking off an investment portfolio on the stock market may seem like a scary prospect. Mark Hartley details a few…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

2 spectacular growth stocks to consider buying in March

Investors ignore the risks with growth stocks when things are going well. But when this changes, fixating on the dangers…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Why is the FTSE 100 suddenly beating the S&P 500?

The UK's blue-chip index has been on fire over the past couple of years, helping it catch up to the…

Read more »

Artillery rocket system aimed to the sky and soldiers at sunset.
Investing Articles

This non-oil FTSE stock’s risen 4.6% in 3 days. What’s going on?

Against the backdrop of trouble in the Middle East, James Beard investigates why this FTSE 100 stock’s doing so well.…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Has a 2026 stock market crash just come a whole lot closer?

If we're in for a stock market crash, what's the best way for us to prepare, and what kinds of…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Up 79% in a year, this FTSE 250 stock still gets a resounding Strong Buy from analysts

This under-the-radar growth stock in the FTSE 250 has been on fire over the past 12 months. Why are City…

Read more »